TBTheodosios Bisdas

Theodosios Bisdas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Theodosios Bisdas has a total of 236 co-authors. Here are the top co-authors by number of shared publications:

  • Giovanni Torsello

    Clinic for Vascular Surgery, St. Franziskus Hospital and University Clinic of Muenster, Muenster, Germany

    7 shared publications
  • Konstantinos Stavroulakis

    Clinic of Vascular Surgery, St. Franziskus Hospital, Münster, Germany

    6 shared publications
  • Arne Stachmann

    Department of Vascular Surgery, St Franziskus Hospital Münster GmbH, Münster, Germany

    4 shared publications
  • Nikolas Charalambous

    Clinic of Vascular and Interventional Radiology, Aretaeio Hospital, Nicosia, Cyprus

    4 shared publications
  • Efthymios Beropoulis

    Division of Vascular Surgery, 2nd Department of Surgery, Faculty of Medicine, “G. Gennimatas” General Hospital of Thessaloniki, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece

    3 shared publications
  • Giovanni Torsello

    Department of Cardiac, Thoracic and Vascular Surgery, University Medical Centre Göttingen, Germany

    3 shared publications

Latest Publications

  • Early Multicentre Outcomes of Endovascular Aortic Arch Repair Using a Custom-Made Triple-Branch NEXUS TRE Endograft System (TRE-ASURE Study)

    by Prakash Saha, Michele Antonello, Theodosios Bisdas, Semih Buz, Ignacio Michel, Marina Ansuategui, Rafael García-Borbolla Fernández, Angel Flores Herrero, Gino Gemayel, Giacomo Isernia, et al.

    Objective: To report the first multicentre European experience with the custom-made NEXUS TRE triple-branch endograft for fully endovascular, debranch-free repair of complex aortic arch pathology, focusing on technical feasibility and early safety outcomes. Methods: This retrospective multicentre analysis included 21 consecutive patients treated with the NEXUS TRE system across 13 European centres between August 2024 and October 2025. Baseline characteristics, procedural metrics, and early (≤30-day) outcomes were assessed. The primary endpoint was device technical success. Secondary endpoints included 30-day mortality, neurological events, spinal cord ischaemia, device-related reintervention, branch patency, and endoleaks. Results: The median age was 75 years (range 59-86), and 19 patients (90.5%) were male. Indications included degenerative aortic arch aneurysm in 11 patients (52.4%) and aneurysmal degeneration following chronic dissection in 10 (47.6%). Primary technical success of the NEXUS TRE device was achieved in 20/21 patients (95.2%), with assisted technical success in 21/21 (100%). There was no in-hospital or 30-day mortality, and no disabling stroke or spinal cord ischaemia occurred. Two patients (9.5%) had nondisabling ischaemic strokes, both with diffusion-weighted-MRI–confirmed embolic infarction; a third patient developed a transient left vocal-cord palsy on a background of established infarcts, without new acute infarction on MRI. All symptoms resolved without disabling deficit (30-day modified Rankin Scale <2). Median procedure time was 227 minutes (IQR 200-278), fluoroscopy time 68.3 minutes (IQR 55.5-87.0), and contrast volume 145 mL (IQR 100-160). One type Ic endoleak that was identified on completion angiography (at the left subclavian bridging stent) was treated intra-operatively with no residual leak. Two type II endoleaks were managed conservatively, with no type Ia, type Ib, or persistent type III endoleak noted on postoperative CT angiography, with all supra-aortic target vessels remaining patent. Conclusions: In this first multicentre European experience, the custom-made NEXUS TRE triple-branch system demonstrated high device technical success and an encouraging early (30-day) safety profile in selected high-risk patients. These findings support the feasibility of fully endovascular, debranch-free multi-branch repair of the aortic arch. Larger studies with longer follow-up are now required to assess durability. Clinical Impact: This first multicentre European experience suggests that fully endovascular, debranch-free aortic arch repair using the custom-made NEXUS TRE triple-branch system is technically feasible in selected high-risk patients unsuitable for open repair. In 21 patients treated across 13 European centres, primary device technical success was 95.2%, assisted technical success was 100%, and no 30-day mortality, disabling stroke, spinal cord ischaemia, or target vessel occlusion occurred. These preliminary findings support further evaluation of triple-branch endografting as a less invasive strategy for complex aortic arch pathology.

  • Open Access

    Early Multicenter Experience with the Nexus Duo™ Aortic Arch Stent Graft System in the Treatment of Aneurysmatic Aortic Arch Diseases

    by Theodosios Bisdas, Michael Erb, Nikolas Charalambous, Michelle Antonello, Vladimir Makaloski, Luis Miguel Izquierdo Lamoca, Said Abisi, Ahmed Elbasty, Semih Buz, Elisa Jankwitz, et al.


  • Open Access

    Preclinical Feasibility of Robotic Peripheral Endovascular Interventions: A Cadaveric Study

    by Emiel Wm. Huistra, Theodosios Bisdas, Leona Damalakiene, Clark J. Zeebregts, Tomas Baltrunas, Iris Q. Grunwald

  • Open Access

    Inner Branch Off the Shelf Technology for Chronic Post-dissection Thoraco-Abdominal Aneurysm with Narrow True Lumen: Results of a European Multicentre Study

    by Giovanni Tinelli, Mario Lescan, Simona Sica, Michele Piazza, Theodosios Bisdas, Vladimir Makaloski, Luca Bertoglio, Fabio Verzini, Giovanni Pratesi, Yamume Tshomba, et al.


  • Early Experience With the Nexus Aortic Arch Endograft for Endovascular Treatment of Complex Aortic Arch Pathologies Beyond Standard Indications

    by Theodosios Bisdas, Neophytos Zambas, Marios Zertalis, George Kanellopoulos, Apostolos Roubelakis, Georgios P. Georghiou, Stylianos Pappas, Panagiotis Theodoridis, Christos Dimopoulos, Nikolaos Iatrou, et al.

    Background: The Nexus stent graft offers a minimally-invasive option for treating aortic arch aneurysms (AArA). Despite strict instructions for use (IFU), it is sometimes applied in complex anatomies for patients who are surgically inoperable or unsuitable for other devices. This study evaluates outcomes in patients treated outside the IFU, providing real-world insights. Methods: We analyzed patients treated with the Nexus endograft outside its IFU between January 2022 and August 2024. The primary endpoint was the occurrence of major adverse cardiovascular and cerebral events (MACCE) such as death, stroke, or myocardial infarction. Secondary endpoints included the reasons for outside-IFU implantation, technical success, any aortic-related adverse events and postoperative endoleaks. Results: Thirteen patients underwent endovascular treatment for AArA outside IFU. Five (38.5%) had a post-type A dissection, 5 had de novo AArA (38.5%), and 3 (23%) lacked a landing zone in zones 1 to 3 of the aortic arch for thoracoabdominal aortic repair. Seven patients (54%) received the Nexus One device, while 6 (46%) received the Nexus Duo endograft. No perioperative MACCE occurred. Mean follow-up was 17 ± 12 months, with a 79% survival rate at 1 year. Primary reasons for outside IFU use included an inner ascending length 40 mm in 46% of patients accordingly. Technical success was achieved in all cases. A type Ic endoleak (7%) due to aneurysmatic degeneration of the brachiocephalic artery was identified at 2 years. No further aortic-related adverse events were reported. Conclusions: The Nexus endograft demonstrated a favorable safety profile and promising clinical outcomes at 1 year, even in patients treated outside IFU criteria, with high technical success and no evidence of stroke. Reassessment of certain IFU criteria could enhance the device’s applicability. Clinical Impact: Our findings highlight the potential for expanding the clinical use of the Nexus stent-graft beyond its current IFU, offering a safe and effective alternative for complex aortic arch anatomies. With high technical success and no perioperative cerebrovascular events, these results suggest that carefully selected patients who are otherwise ineligible for surgery may still benefit from endovascular repair. This study provides real-world evidence supporting the reconsideration of IFU criteria, potentially broadening treatment options. The innovation lies in demonstrating that even outside IFU conditions, the Nexus endograft maintains a strong safety profile, paving the way for more inclusive patient selection.


  • Open Access

    Pudendal Nerve Irritation as Unique Symptom of Pelvic Congestion Syndrome

    by Christos Dimopoulos, Sotirios Bisdas, Theodosios Bisdas

    Pelvic congestion syndrome (PCS) is an underdiagnosed but not rare cause of chronic pelvic pain, affecting approximately 10%–30% of women of reproductive age. It is characterized by venous insufficiency and dilation of the ovarian and pelvic veins, often presenting with symptoms that worsen during menstruation or prolonged standing, and improve in the supine position. Dyspareunia and a sensation of pelvic heaviness are also frequently reported. Neurological manifestations—such as pudendal or femoral nerve irritation—are rare but may offer key diagnostic clues. We present a case of a 30‐year‐old woman with right‐sided pelvic pain radiating to the groin and proximal thigh, consistent with neural irritation. Magnetic neurography revealed dilated pelvic veins in close proximity to the right psoas muscle and the L5 nerve root, suggesting perineural venous engorgement. Selective venography confirmed bilateral ovarian vein insufficiency, and the patient underwent successful embolization with Ruby coils and adjunct sclerotherapy. Postoperative recovery was uneventful, with complete resolution of symptoms. Follow‐up at 1 year showed no recurrence, and the patient later achieved a successful pregnancy. This case highlights the potential for pelvic venous congestion to mimic or cause neural symptoms and emphasizes the diagnostic value of magnetic neurography in complex pain presentations. Endovascular treatment proved safe and effective, even in cases with neurological involvement.


  • Real-World Evaluation of the Off-the-Shelf Precannulated Inner-Branched Endograft for Pararenal Aortic Aneurysms

    by Theodosios Bisdas, Neophytos Zambas, Marios Zertalis, Panagiotis Theodorides, Nikolaos Iatrou, Christos Dimopoulos, Nikolas Charalambous

    Purpose: To analyze the early performance and efficacy of the first commercially available off-the-shelf precannulated multibranched endograft in the endovascular repair of pararenal abdominal aortic aneurysms (PAAAs). The device received European marketing approval in late 2020. Materials and methods: Between January 2021 and June 2023, a retrospective analysis of prospectively collected data from all consecutive patients with pAAAs undergoing implantation of the E-nside precannulated inner-branched endograft was conducted in 2 centers. The primary outcome measure was technical success defined as the composite endpoint of successful (1) delivery of the 24F endograft, (2) use of the precannulation tubes, and (3) implantation of the bridging stent-grafts (BSGs) to the target vessels. Main secondary endpoints were mortality, target vessel instability (TVI), absence of type I or III endoleak, reintervention, spinal cord ischemia, and supra-celiac aortic coverage. Results: Twenty-one patients (20 men, mean age: 71 years) were included in this study with a mean follow-up of 14±7.7 months. Nine patients had a symptomatic aneurysm (43%). Technical success amounted to 95% (in one patient, an iliofemoral conduit was necessary to advance the device). One out of 112 BSGs (1%, right renal artery) occluded at 30 days, resulting in freedom from TVI and reintervention rate at 12 months of 95%. No type I or III endoleaks were identified during follow-up. One patient (5%) died at 13 months due to non-aneurysm-related death, and 1 patient (5%) developed spinal cord ischemia. No other major perioperative complications were observed. Mean supra-celiac aortic coverage reached 52±8%. Conclusions: Given the imperative need for an off-the-shelf endograft tailored to address PAAAs, the E-nside stent-graft demonstrated encouraging outcomes in this study. Nevertheless, it is essential to emphasize that the extent of aortic coverage mandates the production of a truncated variant. Clinical Impact: The endovascular repair of urgent pararenal aortic aneurysms remains still an unsolved problem in the endovascular era since there are no available off-the-shelf dedicated fenestrated or branched endografts. This paper confirms the safety and efficacy of the off-the-shelf precannulated inner branched endograft for this specific indication.


  • Open Access

    Outcomes After Open Surgical, Hybrid, and Endovascular Revascularization for Acute Limb Ischemia

    by Nikolaos Konstantinou, Angeliki Argyriou, Felicitas Dammer, Theodosios Bisdas, Gregory Chlouverakis, Giovanni Torsello, Nikolaos Tsilimparis, Konstantinos Stavroulakis

    Purpose: To report the performance of surgical treatment (ST), hybrid treatment (HT), and endovascular treatment (ET) for patients with acute limb ischemia (ALI). Methods: This is a retrospective, comparative study of all consecutive patients with ALI treated in 2 tertiary centers between April 2010 and April 2020. Amputation and/or death (amputation-free survival; AFS) was the primary composite endpoint. Mortality, major amputation, and reintervention during follow-up were additionally analyzed. Proportional hazards modeling was used to identify confounders, results are presented as hazard ratio (HR) and 95% confidence intervals (CIs). Results: In total, 395 patients (mean age=71.1±13.6 years; 51.1% female) were treated during the study period. Surgical treatment was preferred in 150 patients (38%), while 98 were treated by HT (24.8%) and 147 by ET (37.2%). Rutherford class IIa was the most common clinical presentation in the ET group (50.3%), whereas Rutherford IIb was most common in the ST (54%) and HT (48%) groups (p<0.001). Significantly, more patients presented with a de novo lesion in the ST and HT groups (79.3% and 64.3%, respectively) compared with ET (53.7%; p<0.001). Median follow-up was 20 months (range=0–111 months). In the multivariate analysis, ET showed significantly better AFS during follow-up compared with ST (HR=1.89, 95% CI=1.2–2.9, p<0.001) and HT (HR=1.73, 95% CI=1.1–3.1, p<0.001). Mortality during follow-up was also significantly lower after ET compared with ST (HR=2.21, 95% CI=1.31–3.74, p=0.003) and HT (HR=2.04, 95% CI=1.17–3.56, p=0.012). Endovascular treatment was associated with lower amputation rate compared with ST (HR=2.27, 95% CI=1.19–4.35, p=0.013) but was comparable with HT (HR=2.00, 95% CI=0.98–4.06, p=0.055). Reintervention rates did not differ significantly between the groups (ET vs ST: HR=1.52, 95% CI=0.99–2.31, p=0.053; ET vs HT: HR=1.3, 95% CI=0.81–2.07, p=0.27). Conclusion: Endovascular treatment for ALI was associated with improved AFS and comparable reintervention rates compared with open surgical and hybrid therapy. Clinical Impact: Treatment of acute lower limb ischemia remains a challenge for clinicians with high morbidity and mortality rates. Endovascular revascularization is considered first line treatment for many and hybrid treatments are becoming more common, however data is limited to either old trials, small series or with short follow-up. We present herein our 10-year experience with all available devices and techniques for open surgical, endovascular and hybrid acute limb ischemia treatments and compare their outcomes.


  • The Association of Spondylitis and Aortic Aneurysm Disease

    by Nikolaos Patelis, Petroula Nana, Konstantinos Spanos, Panagiotis Tasoudis, Alexandros Brotis, Theodosios Bisdas, George Kouvelos